Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today released a new CEO Corner ...
ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor ...
A systematic review of 89 studies identifies 53 microRNAs regulating neuroblastoma cell differentiation, with miR-124, miR-34 ...
A review of preclinical evidence finds that nanomaterials can improve mitochondrial targeting, organelle protection and ...
LONDON--Arini, an alternative asset manager with $22 billion in assets under management as of 31 August 2026, today announces the final close of Arini Direct Lending Fund I. The Fund and related ...
Pantheon has closed its latest global private equity secondaries program with $6 billion in commitments, significantly ...
Stock to buy: The brokerage firm further added that Nykaa saw a significant turnaround in FY26 with a record $1 billion ...
Target is betting is future on busy families and the private-label strategy that grew its Cat & Jack kids clothing brand into ...
Akari's CEO outlines plans for AKTX-101 and the importance of novel ADC payloads in cancer treatment advancements.
Swiggy reported strong Q2 FY27 growth as Instamart GOV rose to ₹9,230 crore, while food delivery adjusted EBITDA hit a record ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results